Magnetic fields in the therapy of parkinsonism.
In a recent Editorial published in this Journal, I presented a new and revolutionary method for the treatment of Parkinson's disease (PD). I reported that extracranial treatment with picoTesla magnetic fields (MF) is a highly effective, safe, and revolutionary modality in the symptomatic management of PD. My conclusion was based on experience gained following the successful treatment of over 20 Parkinsonian patients, two of whom had levodopa-induced dyskinesias. None of the patients developed side effects during a several month period of follow-up. In the present communication, I present two reports. The first concerns four Parkinsonian patients in whom picoTesla MF produced a remarkable and sustained improvement in disability. Three of the patients had idiopathic PD and the fourth patient developed a Parkinsonian syndrome following an anoxic episode. In all patients, treatment with MF was applied as an adjunct to antiParkinsonian medication. The improvement noted in these patients attests to the efficacy of picoTesla MF as an additional, noninvasive modality in the therapy of the disease. The second report concerns two demented Parkinsonian patients in whom treatment with picoTesla MF rapidly reversed visuospatial impairment as demonstrated by the Clock Drawing Test. These findings demonstrate, for the first time, the efficacy of these MF in the amelioration of cognitive deficits in Parkinson's disease. Since Alzheimer's pathology frequently coexists with the dementia of Parkinsonism, these observations underscore the potential efficacy of picoTesla MF in the treatment of dementias of various etiologies.
Sandyk
R
R
NeuroCommunication Research Laboratories, Danbury, CT 06811.
D000368:Aged; D001921:Brain / Q000503:physiopathology; D001927:Brain Diseases / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D003072:Cognition Disorders / Q000150:complications / Q000503:physiopathology; D004298:Dopamine / Q000032:analysis / Q000378:metabolism; D004574:Electromagnetic Fields; D005260:Female; D007839:Functional Laterality; D006801:Humans; D008280:Magnetics / Q000627:therapeutic use*; D008297:Male; D008550:Melatonin / Q000032:analysis / Q000378:metabolism; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D011187:Posture; D013028:Space Perception; D014794:Visual Fields
D008550:Melatonin; D004298:Dopamine